Table 1.
Ongoing (recruiting or not yet recruiting) clinical trials of combined epigenetic drug (DNMTi) and other anticancer therapeutic agents (e.g., chemotherapy and immunotherapy).
| Identifier | Study Title | Conditions | Epigenetic Drug | Other Anticancer Drug | Trial Phase | Estimated Enrollment |
|---|---|---|---|---|---|---|
| NCT04049344 | Decitabine Combined with Oxaliplatin in Patients with Advanced Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Decitabine | Oxaliplatin | II | 25 |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients with Relapsed/Refractory Classical Hodgkin Lymphoma | Hodgkin Lymphoma | Decitabine | Camrelizumab | II/III | 100 |
| NCT02159820 | Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer | Primary Malignant Neoplasm of Ovary; FIGO Stages II to IV | Decitabine | Carboplatin-Paclitaxel | II/III | 500 |
| NCT04353479 | Combined PD1 Inhibitor and Decitabine in Elderly Patients with Relapse and Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | Decitabine | Camrelizumab (SHR-1210) | II | 29 |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients with Metastatic Castration Resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue and 7 more | Decitabine | Enzalutamide | Ib/II | 21 |
| NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | Breast Adenocarcinoma; Estrogen Receptor-Negative Breast Cancer; Estrogen Receptor-Positive Breast Cancer and 10 more | Decitabine | Pembrolizumab followed by standard neoadjuvant chemotherapy | II | 32 |
| NCT03295552 | Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC | Metastatic Triple Negative Breast Cancer | Decitabine | Carboplatin | II | 59 |
| NCT03094637 | Azacitidine and Pembrolizumab in Treating Patients with Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome | Azacitidine | Pembrolizumab | II | 40 |
| NCT04490707 | Study of Azacytidine Combined with Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML | Acute Myeloid Leukemia in Remission | Azacitidine | Lenalidomide | III | 60 |
| NCT03019003 | Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients | Head and Neck Cancer | Azacitidine | Durvalumab, Tremelimumab | IB/II | 59 |
| NCT03264404 | Azacitidine and Pembrolizumab in Pancreatic Cancer | Pancreas Cancer | Azacitidine | Pembrolizumab | II | 31 |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Colorectal Adenocarcinoma, CpG Island Methylator Phenotype, Metastatic Microsatellite Stable Colorectal Carcinoma and 5 more | Guadecitabine | Nivolumab | IB/II | 45 |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma | Guadecitabine | Durvalumab | IB/II | 58 |
| NCT03913455 | Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer | Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Guadecitabine | Carboplatin | II | 34 |